Joshua Sharlin, Ph.D.

Washington, D.C. ♦ C: 410-231-8900 ♦ josh.sharlin@fda-expert.net February, 2024 (page 1 of 8)

Professional Summary

Broad and deep skills in drug, biologic and medical device development. Hands-on experience in the entire lifecycle of product development from initial regulatory strategy, clinical trial planning and execution, to submission preparation and review at FDA. Authority in the collection, analysis, interpretation, and presentation of information to FDA. Expert in understanding FDA reviewer's actions and reactions.

Based on experience training over 40,000 staff at FDA-regulated companies on technical and regulatory topics, skilled in explaining FDA related topics to juries.

Worked as an FDA regulatory expert witness in over 50 cases, deposed 16 times and testified 5 times. Specialist in analyzing FDA compliance information to answer three questions: 1) What did the company know and when did they know it? 2) What should the company have known and when should they have known it? 3) What should the company have done and when should they have done it?

Provide FDA related regulatory support to attorneys in cases involving; (i) death or injury caused by drugs, biologics, or medical devices, (ii) patent infringement, (iii) insurance claims, (iv) wrongful termination, (v) trade secrets, (vi) merger and acquisitions, (vii) stock fraud, (viii) software development, (ix) data integrity.

FDA Related Skills, Experience & Qualifications

- Former FDA reviewer
- Improve regulatory strategy
- Audit companies, CROs, vendors and clinical sites for FDA compliance
- Instructor on FDA topics
- Prepare clinical sites and companies for an audit by FDA
- Answer written FDA questions
- Write and improve clinical study protocols and clinical study reports
- Write drug and medical device submissions
- Secret clearance (Dept of Defense)

- Identify and fix data integrity problems
- Audit and improve Trial Master Files
- Evaluate adverse event reporting compliance for drugs and medical devices
- Perform software validation
- Expert witness in lawsuits with an FDA regulatory component
- Speaker at meetings at FDA as a representative of drug and medical device companies
- Expert in analysis and interpretation of FDA safety databases; MAUDE (medical devices), FAERS (drugs)
- Conduct statistical analysis
- Identify, prevent and solve compliance problems

Work History

Consultant & Principal, 06/1994 to Current

Sharlin Consulting, LLC – Washington, D.C.

- In August 2019 completed a 3-year contract as a Drug Development Leadership Advisor. Advise senior Department of Defense leadership on tactical and strategic regulatory actions affecting the path to FDA approval of 19 products (drugs, vaccines and medical devices) under development as medical countermeasures. Write white papers for all programs identifying regulatory strengths, weaknesses and risks affecting progress toward FDA approval. Make and implement recommendations for improvement.
- Audit sponsors, Contract Research Organizations (CROs), clinical sites, labs and software vendors for Good Clinical Practice (GCP) compliance. Identify and close compliance gaps in anticipation of an audit by FDA.
- Write, review and improve INDs, NDAs, PMAs, 510(k)s, protocols and SOPs.
- Solve compliance problems identified by FDA auditors and answer questions posed by FDA reviewers.
- Develop and present more than 40 FDA-related technical, regulatory and compliance topics to over 40,000 people at hundreds of FDA-regulated companies. All were paid presentations.
- Assist sponsors and CROs in FDA compliance of electronic records, software products, databases and software development.
- Investigate, analyze and improve data quality and data integrity in FDA regulated tasks and activities.
- Prepare and present information to FDA at meetings with companies.
- Expert witness in lawsuits regarding matters related to FDA's regulatory process. Deposed in cases involving injuries caused by drugs and medical devices, also trade secrets, wrongful termination, insurance claims, patents, and mergers.

Drug Reviewer, 05/1992 to 06/1994

Food and Drug Administration (FDA) – Rockville, MD

Manage the drug review process. Instruct firms on how to proceed with drug approval. Summarize outstanding problems and issues with protocols and studies and determine if deficiencies were adequately addressed. Review statistical methodology of studies. Author all written communication to the sponsoring firm and integrate comments from other reviewers.

Education

Ph.D. - Physiology, **University of Georgia** – Athens, GA

M.S. - Physiology University of Maryland – College Park, MD

B.A. - Zoology, **University of Iowa** – Iowa City, IA

| Dr. S | Dr. Sharlin's Knowledge and Experience Relevant to Expert Witness Work Table of Contents | | |
|-------|---|--|--|
| Table | Title | | |
| 1 | Eighteen Class Topics About FDA Regulations Developed & Taught by Dr. Sharlin to Staff in FDA Regulated Companies | | |
| 2 | Forty Standard Operating Procedures (SOPs) Written by Dr. Sharlin | | |
| 3 | Sixteen Depositions by Dr. Sharlin | | |
| 4 | Dr. Sharlin has Testified Five Times | | |

| | Table 1 of 4. Eighteen Class Topics About FDA Regulations Developed & Taught by Dr. Sharlin to Staff in FDA Regulated Companies | | | |
|-----|---|--|--|--|
| Row | Class Topic (Dr. Sharlin developed 45 class titles covering these 18 topics.) | Number of Companies Paying to Attend the Class | Total Number of People Attending | |
| 1 | What Needs to be in a Product Submission: An FDA Reviewer's Perspective | 731 | 6,074 | |
| 2 | Avoiding Statistical Errors in Clinical Trials | 385 | 2,873 | |
| 3 | Electronic Records (21 CFR 11) Compliance | 512 | 3,777 | |
| 4 | SAS Software: Programming & Compliance (SAS software is used by FDA and over 90% of FDA-regulated companies for statistical analysis, data management and reporting.) | 615 | 3,331 | |
| 5 | Drug Safety Reporting & Compliance | 421 | 3,346 | |
| 6 | Electronic Submissions – Creation & Compliance | 352 | 2,061 | |
| 7 | How to Write FDA Compliant Standard Operating Procedures (SOPs) | 753 | 5,579 | |
| 8 | Drug Labels and Labeling | 151 | 1,113 | |
| 9 | FDA Reviewer Training | 368 | 3,316 | |
| 10 | Annual Reports: Compliance Requirements for Content | 168 | 1,095 | |
| 11 | Medical Device Safety Reporting & Compliance | 284 | 1,671 | |
| 12 | Planning & Executing Clinical Trials Outside the U.S Compliance Requirements | 175 | 1,112 | |
| 13 | Implementation of Adaptive Design for Clinical Trials | 187 | 1,165 | |
| 14 | ClinicalTrials.gov - Requirements for Entering Information into the Clinical Trials Registration Website | 732 | 3,977 | |
| 15 | 510(k) Medical Device Submissions | 77 | 404 | |
| 16 | Computer System / Software Compliance | 269 | 1,687 | |
| 17 | Integrated Summary of Efficacy Requirements | 84 | 809 | |
| 18 | FDA Requirements for Websites & Social Media | 33 | 221 | |
| | Column Total = | 6,297 | 43,611 | |

| | Table 2 of 4. Forty Standard Operating Procedures (SOPs) Written by Dr. Sharlin |
|----|--|
| 1 | Risk Assessment: Overview and Approach |
| 2 | Risk Assessment: Part 11 Applicability |
| 3 | Risk Assessment Checklist |
| 4 | SOP on SOPs |
| 5 | Device Annual Reports Required of Sponsors and Investigators Before Product Approval |
| 6 | Device Annual Reports Required of A PMA Sponsor, Manufacturer or User Facility |
| 7 | PMA Safety Reporting |
| 8 | Medical Device Reporting (MDR) Requirements for Device User Facilities |
| 9 | Medical Device Reporting Requirements for Device Importers |
| 10 | Medical Device Reporting Requirements for Device Manufacturers |
| 11 | Medical Device Complaint Records |
| 12 | IND (Drug) Safety Reporting |
| 13 | IND (Drug) Annual Reports |
| 14 | Biologics Annual Reporting |
| 15 | Post-Marketing Safety Reporting for Drugs and Biologics: Responsibilities |
| 16 | Post-Marketing Safety Reporting for Drugs and Biologics: Content |
| 17 | Validation of Electronic Adverse Event Data Capture Systems |
| 18 | Data Monitoring Committee – Creation and Activities |
| 19 | Statistical Analysis of Adverse Event Data |
| 20 | MedDRA Coding of Adverse Event Data |
| 21 | Drug Post Approval Annual Reports |
| 22 | Format and Organization Requirements For a Drug Label |
| 23 | Blinding Activities During a Clinical Trial |
| 24 | Initial SAS Software Installation |
| 25 | SAS Software Validation |
| 26 | SAS Software Requirements Specifications |
| 27 | SAS Software Coding Conventions |
| 28 | Debugging SAS Software Logic Errors |
| 29 | SAS Software Log Review |
| 30 | SAS Software Testing |
| 31 | SAS Software Change Control |
| 32 | Archiving and Restoration of Electronic Data |
| 33 | Audit Trails for Electronic Data |
| | |

Joshua Sharlin, Ph.D. - FDA Skills & Expert Witness Experience, Page 6 of 8

| | Table 2 of 4. Forty Standard Operating Procedures (SOPs) Written by Dr. Sharlin |
|----|---|
| 34 | Computer Systems Disaster Recovery |
| 35 | System Access Security |
| 36 | Preparing for an FDA Inspection |
| 37 | Computer and Software Compliance |
| 38 | Technical Review of Submission Documents |
| 39 | Vendor Selection |
| 40 | Transfer of Study Obligations |

| | Table 3 of 4. Sixteen Depositions by Dr. Sharlin |
|----|---|
| 1 | Circuit court of Baltimore City. Deposed on FDA medical device regulatory and submission issues associated with a failed hip implant. |
| 2 | United States District Court, Middle District of Florida, Orlando Division. Deposed on FDA medical device regulatory and submission issues associated with a failed hip implant. |
| 3 | Circuit Court of the 17th Judicial Circuit, In and For Broward County, Florida. Deposed on the role of an Institutional Review Board (IRB) and the responsibilities of IRB members regarding conduct of a clinical trial and the safety of clinical trial subjects. |
| 4 | US District Court, Eastern District of Pennsylvania. Deposed on the regulatory responsibilities of drug manufacturers to provide Medication Guides to patients when they receive a prescription. |
| 5 | US District Court for the District of Oregon. Deposed on the regulatory issues involving patent infringement of a medical device. |
| 6 | Court of the Chancery of the State of Delaware. Deposed on regulatory issues regarding meeting drug development milestones in a merger agreement between a small biotech company and a large pharmaceutical company. |
| 7 | US District Court, Northern District of Illinois Eastern Division. Deposed on regulatory issues regarding the failure of a drug company to properly investigate the relationship between the use of their drug and the likelihood of heart attacks and stroke. |
| 8 | U.S. District Court, Minnesota. Deposed on the failure of a device company to accurately inform FDA about the frequency and cause of their medical device catching fire and the company's failure to fix the problem. |
| 9 | Circuit Court of the Sixth Judicial Circuit, Champaign County, Illinois. Deposed on the regulatory issues associated with the detection and analysis of brain catheter failures. |
| 10 | United States District Court Middle District of Louisiana, Deposed on a large pharmaceutical company's lack of regulatory compliance and actions regarding the association between Nexium and gastric cancer. |
| 11 | State of New Mexico County of Santa Fe, First Judicial District Court. Deposed on the non-compliant off-label promotion of AndroGel by the Defendants. |
| 12 | Court of the Third Judicial Circuit Madison County, Illinois. Deposed on Defendant's lack of regulatory compliance and actions regarding Zantac and its breakdown into and contamination with NDMA, a carcinogen. |
| 13 | Superior Court of the State of Washington, Snohomish County. Implantation of an unapproved version of an artificial ankle. |
| 14 | US District Court for the Western District of Texas, San Antonio Division, Deposed on off-label use of a sealant applied to a bone repair matrix medical device. |
| 15 | US District Court, Central District of California, Southern Division. A patent infringement case involving a neuromodulation medical device. |
| 16 | Missouri Circuit Court, 22 nd Judicial Circuit, City of St Louis. Deaths of preterm infants from necrotizing enterocolitis (NEC) after fed formula. |

| | Table 4 of 4. Dr. Sharlin has Testified Five Times |
|---|---|
| 1 | State of New York Supreme Court. Damages case for a birth defect. Testified about the FDA drug approval process. |
| 2 | Superior Court of the State of California, County of San Diego. A trade secret case. |
| 3 | US District Court, Northern District of Illinois, Eastern Division. Testified in a failure to warn case regarding injury from a cardiac event caused by Androderm, a testosterone replacement therapy drug. |
| 4 | US District Court, Southern District of Mississippi. Testified in a failure to warn case regarding injury caused by a gastric balloon medical device. |
| 5 | International Trade Commission. Trade secret case. Testified about predicting the likelihood of a drug being approved by FDA. |